Pharvaris N.V. (NASDAQ:PHVS) Given Average Rating of “Moderate Buy” by Analysts

Pharvaris N.V. (NASDAQ:PHVS) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $40.5556.

PHVS has been the topic of several recent research reports. Guggenheim increased their price objective on Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Wedbush increased their price target on shares of Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Bank of America boosted their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Thursday, December 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th.

Pharvaris Stock Performance

Pharvaris stock opened at $27.51 on Thursday. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $29.80. The stock has a market cap of $1.44 billion, a P/E ratio of -8.57 and a beta of -2.79. The firm’s fifty day moving average price is $25.57 and its 200-day moving average price is $23.56.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08. On average, analysts predict that Pharvaris will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PHVS. TFG Asset Management GP Ltd boosted its stake in shares of Pharvaris by 48.1% during the second quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock valued at $3,311,000 after purchasing an additional 61,105 shares during the period. TD Asset Management Inc increased its stake in shares of Pharvaris by 27.4% in the second quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock worth $1,751,000 after buying an additional 21,388 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Pharvaris during the 2nd quarter valued at $57,000. Palumbo Wealth Management LLC boosted its position in Pharvaris by 3.2% during the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after buying an additional 447 shares during the period. Finally, HighVista Strategies LLC grew its holdings in Pharvaris by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock worth $418,000 after acquiring an additional 971 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.